A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
- Conditions
- Major Depressive Disorder
- Interventions
- Registration Number
- NCT01372150
- Lead Sponsor
- Pfizer
- Brief Summary
This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 340
- Age >=7 and <18 years of age
- Primary diagnosis of major depressive disorder (MDD)
- CDRS-R score >40
- History of suicidal behaviour, or requires precaution against suicide
- Not in generally healthy medical condition
- History of psychosis or bipolar disorder
- Seizure disorder
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description DVS SR desvenlafaxine succinate sustained release - Fluoxetine fluoxetine Active control for assay sensitivity Placebo placebo -
- Primary Outcome Measures
Name Time Method Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score Baseline and Week 8 Clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses were resolved by using most impaired rating given by valid informant. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment). Total score calculated as sum of the 17 items (range 1 to 119); higher score indicates greater impairment. Adjusted mean presented.
- Secondary Outcome Measures
Name Time Method Change From Baseline to Week 8 in the Clinical Global Impression of Severity (CGI-S) Score Baseline and Week 8 A 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. Change: score at observation minus score at baseline. Adjusted mean presented.
Percentage of Participants by Clinical Global Impression Improvement (CGI-I) Score at Weeks 1, 2, 3, 4, 6, and 8 Baseline and Weeks 1, 2, 3, 4, 6, and 8 A 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.
Percentage of Participants With a CGI-I Response Defined as a Score of 'Very Much Improved' or 'Much Improved' Weeks 1, 2, 3, 4, 6, and 8 A 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.
Trial Locations
- Locations (43)
Harmonex Neuroscience Research, Inc.
🇺🇸Dothan, Alabama, United States
Dedicated Clinical Research
🇺🇸Goodyear, Arizona, United States
University of Arizona Clinical and Translational Science Center (CATS)
🇺🇸Tucson, Arizona, United States
University of Arizona College of Medicine Dept of Psychiatry
🇺🇸Tucson, Arizona, United States
Arkansas Psychiatric Clinic Clinical Research Trials, P.A.
🇺🇸Little Rock, Arkansas, United States
ATP Clinical Research, Inc. 1
🇺🇸Costa Mesa, California, United States
Behavioral Research Specialists, LLC
🇺🇸Glendale, California, United States
Synergy Clinical Research Center
🇺🇸National City, California, United States
Neuropsychiatric Research Center of Orange County
🇺🇸Orange, California, United States
Pacific Clinical Research Medical Group
🇺🇸Orange, California, United States
Scroll for more (33 remaining)Harmonex Neuroscience Research, Inc.🇺🇸Dothan, Alabama, United States